Drug Profile
Halystatin
Latest Information Update: 12 Jun 2000
Price :
$50
*
At a glance
- Originator Takeda
- Class Antiplatelets; Calcium regulators; Osteoporosis therapies
- Mechanism of Action Integrin alphaVbeta3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Postmenopausal osteoporosis
Most Recent Events
- 12 Jun 2000 Profile reviewed but no significant changes made
- 07 Sep 1998 No-Development-Reported for Postmenopausal osteoporosis in Japan (Unknown route)
- 21 Jun 1995 An in vitro study has been added to the pharmacodynamics section